top of page

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Sep 16, 2025
1 min read

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated at AstraZeneca, though Cinclus owns it outright today, and is in a phase 3 that just started.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page